Drugs / Tilsotolimod
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04270864 | Apr 2020 → Jul 2021 | — | Gustave Roussy, Cancer Campus, Grand Paris | Terminated | No outcome recorded |
| Phase 1 | NCT04196283 | Jan 2020 → Oct 2022 | cancer of unknown primary site | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03052205 | Jun 2017 → Jul 2019 | melanoma, refractory malignant neoplasm | Idera Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00990938 | Sep 2009 → May 2010 | — | Idera Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00728936 | Sep 2007 → Dec 2009 | hepatitis C virus infection | Idera Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT04126876 | Jan 2020 → Nov 2021 overdue | melanoma | A.J.M. van den Eertwegh | Recruiting | No outcome recorded |
| Phase 2 | NCT03865082 | Oct 2019 → Mar 2022 overdue | cancer | Idera Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02644967 | Dec 2015 → Feb 2020 | metastatic melanoma | Idera Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03445533 | May 2018 → Jun 2021 | metastatic melanoma | Idera Pharmaceuticals, Inc. | Terminated | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tilsotolimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03865082 ↗ |
| Known as | IMO 2125 | “IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.” NCT00990938 ↗ |
| Action | Activate | “synthetic DNA-based agonist of Toll-like receptor 9 (TLR9)” NCT00728936 ↗ |
| Modality | Oligonucleotide (other) | “IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9)” NCT00728936 ↗ |
| Route | Subcutaneous | “receive a subcutaneous injection once per week for 4 weeks” NCT00990938 ↗ |
| Target | TLR9 | “agonist of Toll-like receptor 9 (TLR9)” NCT00728936 ↗ |